Home » Stocks » CWBR

CohBar, Inc. (CWBR)

Stock Price: $1.12 USD -0.02 (-1.75%)
Updated Jul 28, 2021 4:00 PM EDT - Market closed
After-hours: $1.14 +0.02 (1.79%) Jul 28, 7:37 PM
Market Cap 69.51M
Revenue (ttm) n/a
Net Income (ttm) -16.09M
Shares Out 61.79M
EPS (ttm) -0.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 28
Last Price $1.12
Previous Close $1.14
Change ($) -0.02
Change (%) -1.75%
Day's Open 1.12
Day's Range 1.11 - 1.16
Day's Volume 219,200
52-Week Range 0.85 - 2.22

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CohBar Inc (NASDAQ: CWBR) has updated the timing for releasing Phase 1a/1b trial data of CB4211 for the potential treatment of nonalcoholic steatohepatitis (NASH) and obesity.  The process of data entry...

2 weeks ago - Benzinga

MENLO PARK, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

2 weeks ago - GlobeNewsWire

MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

1 month ago - GlobeNewsWire

Company to host conference call at 5:00 p.m. ET Company to host conference call at 5:00 p.m. ET

2 months ago - GlobeNewsWire

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

2 months ago - GlobeNewsWire

Announces change to the Board of Director's Chair Announces change to the Board of Director's Chair

3 months ago - GlobeNewsWire

CWBR, KL, MUX, NSANY, and PAA have been added to the Zacks Rank #5 (Strong Sell) List on April 22, 2021

Other stocks mentioned: KL, MUX, NSANY, PAA
3 months ago - Zacks Investment Research

MENLO PARK, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend...

3 months ago - GlobeNewsWire

MENLO PARK, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend...

3 months ago - GlobeNewsWire

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

3 months ago - GlobeNewsWire

MENLO PARK, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend...

3 months ago - GlobeNewsWire

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

4 months ago - GlobeNewsWire

MENLO PARK, Calif., March 12, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend...

4 months ago - GlobeNewsWire

MENLO PARK, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend...

4 months ago - GlobeNewsWire

MENLO PARK, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

5 months ago - GlobeNewsWire

MENLO PARK, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

6 months ago - GlobeNewsWire

MENLO PARK, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

7 months ago - GlobeNewsWire

MENLO PARK, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

8 months ago - GlobeNewsWire

CohBar, Inc. (CWBR) CEO Steve Engle on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

8 months ago - GlobeNewsWire

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

8 months ago - GlobeNewsWire

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

Other stocks mentioned: CI, DRRX, GRFS, PTI
8 months ago - Zacks Investment Research

MENLO PARK, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

8 months ago - GlobeNewsWire

MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

9 months ago - GlobeNewsWire

Company to host a Key Opinion Leader webinar on the current treatment landscape in IPF, the unmet need, and positive findings from preclinical studies of CohBar's CB5138 Analogs on Friday, November 6 at...

9 months ago - GlobeNewsWire

MENLO PARK, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

9 months ago - GlobeNewsWire

MENLO PARK, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

9 months ago - GlobeNewsWire

MENLO PARK, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend ...

9 months ago - GlobeNewsWire

MENLO PARK, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exte...

9 months ago - GlobeNewsWire

MENLO PARK, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exte...

10 months ago - GlobeNewsWire

MENLO PARK, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exte...

10 months ago - GlobeNewsWire

MENLO PARK, Calif., Aug. 28, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic di...

11 months ago - GlobeNewsWire

MENLO PARK, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic di...

11 months ago - GlobeNewsWire

MENLO PARK, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic di...

11 months ago - GlobeNewsWire

MENLO PARK, Calif., Aug. 24, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exten...

11 months ago - GlobeNewsWire

CohBar, Inc. (CWBR) CEO Steve Engle on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

New positive preliminary preclinical results in ARDS model Company to host conference call and webcast at 5:00 p.m. ET

11 months ago - GlobeNewsWire

In vivo data demonstrates antifibrotic effects of multiple novel peptide analogs in preclinical models of idiopathic pulmonary fibrosis (IPF) In vivo data demonstrates antifibrotic effects of multiple n...

11 months ago - GlobeNewsWire

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

11 months ago - GlobeNewsWire

MENLO PARK, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exten...

1 year ago - GlobeNewsWire

MENLO PARK, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exten...

1 year ago - GlobeNewsWire

MENLO PARK, Calif., June 30, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and exten...

1 year ago - GlobeNewsWire

MENLO PARK, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend...

1 year ago - GlobeNewsWire

CohBar, Inc. (CWBR) CEO Steve Engle on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Former senior executive to continue on CohBar Board of Directors Former senior executive to continue on CohBar Board of Directors

1 year ago - GlobeNewsWire

CohBar Looks Undervalued Ahead Of Upcoming Data Readout

1 year ago - Seeking Alpha

Preclinical Testing of CB5064 Analogs Initiated in ARDS Preclinical Testing of CB5064 Analogs Initiated in ARDS

1 year ago - GlobeNewsWire

MENLO PARK, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend...

1 year ago - GlobeNewsWire

COVID-19 Pandemic Impact at Clinical Sites Delays Study COVID-19 Pandemic Impact at Clinical Sites Delays Study

1 year ago - GlobeNewsWire

CohBar's (CWBR) CEO Steve Engle on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About CWBR

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, acute respiratory distress syndrome, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of ... [Read more...]

Industry
Biotechnology
Founded
2007
Stock Exchange
NASDAQ
Ticker Symbol
CWBR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for CohBar stock is "Strong Buy." The 12-month stock price forecast is 5.83, which is an increase of 420.54% from the latest price.

Price Target
$5.83
(420.54% upside)
Analyst Consensus: Strong Buy